Survival impact of second primary cutaneous and non‐cutaneous melanoma in melanoma survivors
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Jingjing Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Group of Epidemiology, University of California Davis, Davis, California, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Neoplasms, Second Primary, Cancer Survivors. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Melanoma survivors have a high risk of developing second primary neoplasms, both cutaneous melanoma (SPCM) and non‐cutaneous melanoma (SPNCM), but little is known about the survival impact of the diagnosis of SPCM and SPNCM.
Objective
To compare overall survival between melanoma survivors with first primary melanoma and SPCM/SPNCM by stage at diagnosis of second primary neoplasms.
Methods
Among cutaneous (CM) and non‐cutaneous melanoma (NCM) survivors of all ages, SPCM ( N = 7314) or SPNCM ( N = 157) between 2004 and 2020 were identified from the Surveillance, Epidemiology, and End Results 17 Research Plus database. Flexible parametric modelling was conducted to evaluate the time‐varying effect of SPCM and SPNCM, compared to single melanoma, on survival.
Results
Over the study period, 3.4% of patients had a SPCM (12.9% regional/distant‐stage) and 0.1% had a SPNCM (36.3% regional/distant or unknown‐stage). Compared with single CM, patients with SPCM (regional/distant‐stage hazard ratio [HR] = 1.71, 95% confidence interval [CI] = 1.55–1.89; localized‐stage HR = 1.09, CI = 1.01–1.18) and regional/distant‐stage SPNCM (Year 1: HR = 1.56, CI = 0.81–3.03) had worse overall survival. Among NCM survivors, regional/distant‐stage SPCM (HR = 2.67, CI = 1.73–4.13) had a more pronounced impact on decreased overall survival than localized‐stage SPCM (HR = 1.19, CI = 0.71–1.99) when compared with single NCM, with similar trends seen for regional/distant‐stage SPNCM (Year 2: HR = 1.39, CI = 0.76–2.54) relative to localized‐stage SPNCM (Year 2: HR = 0.96, CI = 0.61–1.50).
Conclusions
The reduction in survival among melanoma survivors with SPCM and SPNCM suggests the potential need for prevention and early detection of SPCM and SPNCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Group of Epidemiology, University of California Davis, Davis, California, USA.
- Department of Dermatology, University of California Davis, Sacramento, California, USA.
- Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, California, USA.
- Department of Public Health Sciences, School of Medicine, University of California, Davis, California, USA.
- Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis Comprehensive Cancer Center, Sacramento, California, USA.
ORCID-Profile: Jingjing Xie, Maija Kiuru
Zitieren
APA
Xie, J., Kiuru, M., Pollock, B. H., & Keegan, T. H. M. (2025). Survival impact of second primary cutaneous and non‐cutaneous melanoma in melanoma survivors. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70043
Vancouver
Xie J, Kiuru M, Pollock BH, Keegan THM. Survival impact of second primary cutaneous and non‐cutaneous melanoma in melanoma survivors. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.70043
BibTeX
@article{Xie2025,
author = {Xie, Jingjing and Kiuru, Maija and Pollock, Brad H and Keegan, Theresa H M},
title = {Survival impact of second primary cutaneous and non‐cutaneous melanoma in melanoma survivors},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.70043}
}
EUVIMED